Home -> Law Blog Directory -> Patent Law Blogs -> Patent Baristas
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patent BaristasSenate Committee: 12 Years of Data Exclusivity is Cool
By Stephen Albainy-Jenei
“To amend the public health service act to establish a pathway for the licensure of biosimilar biologic products, to promote innovation in the life sciences.” Amendment No. 297.
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee voted Monday in favor of a proposal by Sens. Kay Hagan (D-NC), Michael Enzi (R-WY), and Orrin Hatch (R-UT) to create a follow-on biologics (FOB) pathway that provides 12 years of data exclusivity for brand-name biologic drugs.
The measure passed 16 to 7, despite an earlier decree by the Obama administration that a seven-year exclusivity limit sounded good.
The committee considered several other proposals including voting down one by Sen. Sherrod Brown (D-OH), which would have provided only 7 years of exclusivity for brand name biologics. Sen. Edward M. Kennedy (D-MA), chairman of the HELP committee, voted by proxy to support the 12-year limit.
The vote was a small victory for major biotech drugmakers, which have been pushing for a period of 12 to 14 years before generic equivalents could be approved. Biotech companies have been pushing for a longer period of data exclusivity saying that it can take 15 years and a $1 billion to develop and market a biotech drug so they need the longer period to make back their investment. Generic drugmakers, not surprising, would like the exclusivity period limited to five or seven years.
This is just as small step since the Senate plan could change when the healthcare bill goes to the floor for a vote. It also must be approved by the House.
So, what will the final number be for exclusivity? Try Follow-On Blackjack.
Related posts:
- Economist Argues That 7 Years Ought to be Enough for Biologic Data Exclusivity As Congres
- Administration’s First Volley on Biosimilars: 7 Years of Exclusivity is Long Enough The Obama
- Does Congress Need A Lesson On Biotechnology or Economics? Today
Related posts brought to you by Yet Another Related Posts Plugin.
Full post as published by Patent Baristas on July 14, 2009 (boomark / email).
Foreign Investment and National Security Act of 2007
Strengthens examination requirements of the Committee on Foreign Investment in the United States
Refco
Ex-CEO Gets 16 Years
Nail Guns
Injury Rate More Than Doubles in Three Years
T-mobile data plans, T-mobile, t-mobile phones
T-Mobile Faces Class Action over Limited Unlimited Data Plans
False Arrest
City of Greer pays $50,000 settlement after imprisoning a woman whose charges had been dismissed years earlier.
AT&T Faces Class Action over Excessive Data Usage Charges
AT&T Faces Class Action over Excessive Data Usage Charges
Seroquel
Data on Diabetes Buried

Senators Hatch and Enzi Champion 12-Year Data Exclusivity in Senate
Former House Ways and Means Economist Claims 7-Year Data Exclusivity Period Is Sufficient
BIO CEO Provides Update on Follow-on Biologics Legislation
Senator Kennedy Weighs in on Biosimilar Data Exclusivity Period
Non-Patent Exclusivity and 180-Day Exclusivity Forfeiture Slides Posted
Follow-on Biologics in the News - No. 4








